Logo do repositório
 
Publicação

Non-vitamin K oral anticoagulants assessment in high risk of bleeding patients with non-valvular atrial fibrillation

2022Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorSilva Cunha, Pedro
dc.contributor.authorViveiros Monteiro, André
dc.contributor.authorCoutinho Cruz, Madalena
dc.contributor.authorMalveiro, Paula
dc.contributor.authorReis, João Pedro
dc.contributor.authorPortugal, Guilherme
dc.contributor.authorDias, Ana
dc.contributor.authorFerreira, Rui Cruz
dc.contributor.authorOliveira, Mario
dc.date.accessioned2022-02-25T16:09:53Z
dc.date.available2022-02-25T16:09:53Z
dc.date.issued2022
dc.description© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).pt_PT
dc.description.abstractAtrial fibrillation (AF) is commonly associated with advanced age and the presence of multiple, concomitant acute and chronic health conditions, placing this population at high risk for serious therapeutic side effects. Nonvitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in patients with atrial fibrillation. The purpose of this study was to investigate the effectiveness and safety of NOAC in a group at high risk of bleeding complications, in a real-world setting. We conducted a retrospective analysis of a high-risk cohort of 418 patients (pts) followed-up in our anticoagulation unit; data on patient characteristics, anticoagulation treatment, and bleeding and thrombotic complications were evaluated. The population had a median age of 77.8 ± 10.3 years and the mean CHA2DS2-VASc score was 3.85 (SD ± 1.4). Overall, 289 (69.1%) were ≥75 years old. During a mean follow-up time of 51.2 ± 35.7 months, we observed a rate of any bleeding of 7, a clinically relevant non-major bleeding rate of 4.8, a major bleeding rate of 2.2, a stroke rate of 1.6, and a rate of thrombotic events of 0.28 per 100 patient-years. There were 59 hospitalizations due to any cause (14.1%) and 36 (8.6%) deaths (one due to ischemic stroke). A structured follow-up, with judicious prescribing and drug compliance, may contribute to preventing potential complications.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationGeriatrics (Basel). 2022 Feb 17;7(1):20pt_PT
dc.identifier.doi10.3390/geriatrics7010020pt_PT
dc.identifier.eissn2308-3417
dc.identifier.urihttp://hdl.handle.net/10451/51519
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://www.mdpi.com/journal/geriatricspt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectAnticoagulation unitpt_PT
dc.subjectAtrial fibrillationpt_PT
dc.subjectNon-vitamin K oral anticoagulantspt_PT
dc.titleNon-vitamin K oral anticoagulants assessment in high risk of bleeding patients with non-valvular atrial fibrillationpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.titleGeriatricspt_PT
oaire.citation.volume7pt_PT
person.familyNameMartins Oliveira
person.givenNameMario Joao
person.identifier.ciencia-id2312-2190-19B2
person.identifier.orcid0000-0002-8371-8354
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication81e0b444-8832-47a8-a911-2f89eb33545d
relation.isAuthorOfPublication.latestForDiscovery81e0b444-8832-47a8-a911-2f89eb33545d

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Non_vitaminK.pdf
Tamanho:
534.51 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

FM - Artigos em Revistas Internacionais